Research Article
Volume 12 Issue 2 - 2021
The Efficacy and Safety of 2-Year Treatment with Zoledronic Acid in Patients with Osteoporosis and the Influence of Previous Treatments in Actual Clinical Practice
Fumitoshi Omura*
Koenji Orthopedics Clinic, Tokyo, Japan
*Corresponding Author: Fumitoshi Omura, Koenji Orthopedics Clinic, Tokyo, Japan.
Received: December 17, 2020; Published: January 18, 2021




Abstract

Purpose: To investigate the efficacy and safety of treatment with zoledronic acid (ZOL).

Methods: Retrospective analyses were performed on patients with primary osteoporosis who received ZOL for 24 months. I analyzed some indicators, including changes in BMD (bone mineral density) until 24 months after the start of ZOL administration. Moreover, according to treatments prior to the administration of ZOL, patients were divided into 3 groups and all groups were analyzed. Patients who received ZOL after 18-month administration of 56.5-μg teriparatide formulation for once-weekly use (1/W-TPTD) were also analyzed.

Results: In 41 patients whose data were collected until 24 months after the start of ZOL administration, the lumbar spine BMD was significantly increased from baseline by 5.2% (3.6% - 6.9%) at 6 months after the start of ZOL administration, 6.8% (5.1% - 8.6%) at 12 months, 9.1% (7.3% - 11.0%) at 18 months, and 10.0% (8.1% - 11.9%) at 24 months. The femoral neck BMD was also significantly improved. Regarding previous treatments, the lumbar spine BMD and the femoral neck BMD was maintained/increased in each of 3 groups. In a group of patients who received ZOL after receiving treatment with 1/W-TPTD, ZOL administration significantly increased BMD further. A significant improvement was also observed in visual analog scale score of back pain, total Japanese Osteoporosis Quality of Life Questionnaire (JOQOL) score, and some individual JOQOL scores.

Conclusion: ZOL, which only needs to be administered once a year and has good compliance, can be a useful option for the treatment of osteoporosis.

Keywords: Zoledronic Acid; Teriparatide; Osteoporosis; Bone Mineral Density; Born Turnover Marker

References

  1. Silverman SL., et al. “Oral bisphosphonate compliance and persistence: a matter of choice?”. Osteoporosis International 22 (2011): 21-26.
  2. Imaz I., et al. “Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis”. Osteoporosis International 21 (2010): 1943-1951.
  3. Itoh A., et al. “Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats”. Biological and Pharmaceutical Bulletin 39 (2016): 323-328.
  4. Maria JFL., et al. “Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates”. European Journal of Hospital Pharmacy 26 (2019): 4-9.
  5. Nakamura T., et al. “Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)”. Osteoporosis International 28 (2017): 389-398.
  6. Creation Committee of Guidelines for Prevention and Treatment of Osteoporosis. “Japanese 2015 guidelines for prevention and treatment of osteoporosis”. Life Science Publishing Co. LTD (2015).
  7. Cauley JA., et al. “Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial”. Journal of Bone and Mineral Research 26 (2011): 984-992.
  8. Adachi JD., et al. “Zoledronic acid results in better health-related quality of life following hip fracture: The HORIZON-Recurrent Fracture Trial”. Osteoporosis International 22 (2011): 2539-2549.
  9. Koivisto K., et al. “Efficacy of zoledronic acid for chronic low back pain associated with Modic changes in magnetic resonance imaging”. BMC Musculoskeletal Disorders 15 (2014): 64.
  10. Hadji P., et al. “Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass”. Osteoporosis International 23 (2012): 2043-2051.
  11. Shimizu T., et al. “Sequential treatment with zoledronic acid followed by teriparatide or vice versa increases bone mineral density and bone strength in ovariectomized rats”. Bone Reports 7 (2017): 70-82.
  12. Takahashi H., et al. “A trial of the Japanese Osteoporosis Quality of Life questionnaire 1999 version and a development of 2000 version (in Japanese)”. The Journal of Bone and Mineral Metabolism 18 (2001): 83-101.
  13. Mori Y., et al. “Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker”. Osteoporosis International 29 (2018): 1155-1163.
  14. Fraser LA., et al. “Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis”. Therapeutics and Clinical Risk Management 7 (2011): 157-166.
  15. Black DM., et al. “Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial”. The Journal of the American Medical Association 296 (2006): 2927-2938.
  16. Dunford JE., et al. “Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates”. Journal of Pharmacology and Experimental Therapeutics 296 (2001): 235-242.
  17. Nancollas GH., et al. “Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite”. Bone 38 (2006): 617-627.
  18. Rittmaster RS., et al. “Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate”. The Journal of Clinical Endocrinology and Metabolism 85 (2000): 2129-2134.
  19. Prince R., et al. “Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment”. Journal of Bone and Mineral Research 20 (2005): 1507-1513.
  20. Kawate H., et al. “Alendronate improves QOL of postmenopausal women with osteoporosis”. Clinical Interventions in Aging 5 (2010): 123-131.
  21. Hayashi S., et al. “Denosumab Treatment Improved Health-Related Quality of Life in Osteoporosis: A Prospective Cohort Study”. JBMR Plus 3 (2019): e10191.
  22. Omura F. “Impact of patient background factors on the treatment efficacy of once-weekly teriparatide”. Osteoporos Sarcopenia 5 (2019): 51-56.
  23. Shigenobu K., et al. “The efficacy of osteoporotic treatment in patients with new spinal vertebral compression fracture pain, ADL, QOL, bone metabolism and fracture-healing - In comparison with weekly teriparatide with bisphosphonate”. Bone Reports 11 (2019): 100217.
  24. Nishikawa A., et al. “Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report”. Clinical Interventions in Aging 11 (2016): 913-925.
  25. Watkins LR., et al. “Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states”. Pain 63 (1995): 289-302.
  26. Payne R. “Mechanisms and management of bone pain”. Cancer 80 (1997) :1608-1613.
  27. Cantatore FP., et al. “Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate”. The Journal of Rheumatology 26 (1999): 2318-2323.
  28. D’Amelio P., et al. “Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women”. Journal of Bone and Mineral Research 23 (2008): 373-379.
  29. Silverman SL., et al. “Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid”. Osteoporosis International 22 (2011): 2337-2345.
  30. Wark JD., et al. “Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg”. Osteoporosis International 23 (2012): 503-512.
  31. Okimoto N., et al. “Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ Study”. The Journal of Bone and Mineral Metabolism 38 (2020): 230-239.
  32. Reid IR., et al. “Characterization of and risk factors for the acute-phase response after zoledronic acid”. The Journal of Clinical Endocrinology and Metabolism 95 (2010): 4380-4387.
  33. Cooper C., et al. “Secular trends in the incidence of hip and other osteoporotic fractures”. Osteoporosis International 22 (2011): 1277-1288.
  34. Orimo H., et al. “Hip fracture incidence in Japan: Estimates of new patients in 2012 and 25-year trends”. Osteoporosis International 27 (2016): 1777-1784.
  35. Fujimori K., et al. “Analysis of the persistence and compliance of medications for osteoporosis using E-claim database (in Japanese)”. Japan Osteoporosis Society, Japanese Society 5 (2019): 277-285.
  36. Nakamura T., et al. “Preliminary Survey for Improvement of the Drug Adherence in Osteoporosis Treatment: National Survey on Discontinuation of Bisphosphonate”. Osteoporosis Japan 21 (2013): 627-635.
  37. Papaioannou A., et al. “Patient adherence to osteoporosis medications: problems, consequences and management strategies”. Drugs Aging 24 (2007): 37-55.
  38. Roerholt C., et al. “Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence”. Osteoporosis International 20 (2009): 299-307.
  39. Black DM., et al. “Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group”. The Journal of Clinical Endocrinology and Metabolism 85 (2000): 4118-4124.
Citation: Fumitoshi Omura. “The Efficacy and Safety of 2-Year Treatment with Zoledronic Acid in Patients with Osteoporosis and the Influence of Previous Treatments in Actual Clinical Practice”.EC Orthopaedics 12.2 (2021): 73-86.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before April 26, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk